Drug intelligence / Profile preview

ambroxol + clenbuterol

Development stage
Unknown
Lead developer
Hanmi Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Ambromoterol is a fixed-dose combination drug consisting of ambroxol hydrochloride and clenbuterol hydrochloride, primarily used for the treatment of respiratory conditions. Ambroxol is a mucolytic agent that facilitates the clearance of thick mucus by increasing the secretion of respiratory tract fluid and stimulating surfactant production. Clenbuterol is a potent, long-acting selective beta-2 adrenergic receptor agonist that acts as a bronchodilator by relaxing airway smooth muscle. This combination is particularly effective in pediatric patients suffering from acute or chronic bronchitis, bronchial asthma, and other pulmonary diseases characterized by cough, viscous sputum, and airway obstruction. It is widely marketed in China, where it is a standard treatment for pediatric respiratory distress.

Brand names
Yi Tan Jing
Other names
ambromoterolAmbroxol hydrochloride and Clenbuterol hydrochlorideAmbromoterol oral solution
02

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on ambroxol + clenbuterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ambroxol + clenbuterol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call